December 30th 2023
As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia in urology.
September 28th 2023
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
View More
New York GU 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
March 8-9, 2024
Register Now!
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Optilume BPH System demonstrates sustained improvements in LUTS secondary to BPH
August 14th 2023"The next-generation Optilume BPH Catheter System offers a safe and effective new, minimally invasive treatment for BPH, reducing urinary obstruction with a low rate of sexual or other adverse effects," says Steven A. Kaplan, MD.
Low testosterone and frailty linked with 180-day readmission in men undergoing TURP, PVP
June 19th 2023“Surprisingly, testosterone was not independently associated with frailty on our analysis, but on multivariable analysis, both hospital frailty risk score and low preoperative T were independently associated with 180-day readmission,” says Jasmine Lin, MD.
Study highlights efficacy of prostate artery embolization in BPH
March 5th 2023“This study shows prostate artery embolization to be a safe and highly effective treatment whose long-term outcomes include sustained LUTS relief, significant improvement in quality of life and no change in erectile function,” according to Shivank Bhatia, MD.
Dr. Gill discusses clinical impact of the new wave of BPH treatments
October 23rd 2022In this installment of Urology Times’ 50th Anniversary Innovation Celebration, Bradley Gill, MD, MS, discusses the impact that the new wave of minimally invasive BPH treatments has had for both patients and urologists.
Dr. Gill explains the importance of BPH treatment innovations to urology
October 19th 2022“It’s pretty clear that over the past 50 years we've seen innovations in BPH treatment both from the utilization of technology and also from the patient outcome and experience standpoint,” says Bradley Gill, MD, MS.
Dr. Chughtai discusses new pilot study on Rezum treatment for BPH
October 18th 2022“We found that the adverse event rates have dropped dramatically, to about a third of what it was reported in the pivotal trial, but at the same time still had the same net benefits in terms of efficacy when it comes to Q max, symptomatic improvement, as well as PVR," said Bilal Chughtai, MD.